Is It Safe to Withdraw Aspirin Very Soon After PCI for Acute Coronary Syndromes?

In a randomized trial, maintaining the aspirin was safer for patients taking a potent P2Y12 inhibitor.

After percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS), patients receive dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor. To study whether aspirin can be safely withheld in this clinical setting, researchers conducted an open-label trial, randomizing 3400 patients within 4 days of hospitalization to antithrombotic monotherapy (with ticagrelor or prasugrel) or DAPT. They assessed whether antithrombotic monotherapy (with ticagrelor or prasugrel) would be noninferior to DAPT. Most participants (62%) had ST-segment-elevation myocardial infarction (MI). In the monotherapy group, aspirin was stopped immediately after randomization.

At 12 months, the composite ischemic endpoint — all-cause mortality, M…

Reviewing Author

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Shea E. Hogan, MD, MSCS, FACC, FSCAI, FSVM

Disclosures

Editorial BoardsVascular Medicine

Is It Safe to Withdraw Aspirin Very Soon After PCI for Acute Coronary Syndromes?

Topics

Reviewing Author